Treatment of anemia in myelofibrosis: focusing on Novel Therapeutic Options
Expert Opin Investig Drugs. 2023 Dec 10. doi: 10.1080/13543784.2023.2294324. Online ahead of print.ABSTRACTINTRODUCTION: Myelofibrosis is a clonal myeloproliferative neoplasm associated with the proliferation of hematopoietic stem cells, increased bone marrow fibrosis, extramedullary hematopoiesis, hepatosplenomegaly, abnormal cytokine production, and constitutional symptoms. These and many other factors contribute to the development of anemia in myelofibrosis patients.AREAS COVERED: This review summarizes novel and promising treatments for anemia in myelofibrosis including transforming growth factor-β inhibitors luspater...
Source: Expert Opinion on Investigational Drugs - December 11, 2023 Category: Drugs & Pharmacology Authors: Eren Arslan Davulcu Merve Beyza O ğuz Emre K ılıç Ahmet Emre E şkazan Source Type: research

Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration
CONCLUSIONS: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The PK profiles and safety characteristics in this study indicated that JX11502MA has the potential to be a favorable treatment option for patients with schizophrenia.TRIAL REGISTRATION: https://clinicaltrials.gov (identifier: NCT05233657).PMID:38054696 | DOI:10.1080/13543784.2023.2291470 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - December 6, 2023 Category: Drugs & Pharmacology Authors: Yimin Yu Jingjing He Zhiwei Huang Yan Li Ying Wu Yifeng Shen Yanling Zhou Cungang Bao Zhiping Jin Huafang Li Source Type: research

Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure
Expert Opin Investig Drugs. 2023 Nov 30:1-14. doi: 10.1080/13543784.2023.2290064. Online ahead of print.ABSTRACTINTRODUCTION: Heart failure is a complex, debilitating condition and despite advances in treatment, it remains a significant cause of morbidity and mortality worldwide. Therefore, the need for alternative treatment strategies is essential. In this review, we explore the therapeutic strategies of augmenting natriuretic peptide receptors (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) in heart failure.AREAS COVERED: We aim to provide an overview of the evidence of preclinical and clinical studies on nov...
Source: Expert Opinion on Investigational Drugs - November 30, 2023 Category: Drugs & Pharmacology Authors: Ashwin Ajay Debar Rasoul Alend Abdullah Benjamin Lee Wei En Knievel Mashida Marwan Al-Munaer Hanan Ajay Dileep Duvva Jean Mathew Adeoye Adenaya Gregory Y H Lip Rajiv Sankaranarayanan Source Type: research

Augmentation of natriuretic peptide (NP) receptor a and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signaling as a therapeutic strategy in heart failure
Expert Opin Investig Drugs. 2023 Nov 30. doi: 10.1080/13543784.2023.2290064. Online ahead of print.ABSTRACTINTRODUCTION: Heart failure is a complex, debilitating condition and despite advances in treatment, it remains a significant cause of morbidity and mortality worldwide. Therefore, the need for alternative treatment strategies is essential. In this review, we explore the therapeutic strategies of augmenting natriuretic peptide receptors (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) in heart failure.AREAS COVERED: We aim to provide an overview of the evidence of preclinical and clinical studies on novel he...
Source: Expert Opinion on Investigational Drugs - November 30, 2023 Category: Drugs & Pharmacology Authors: Ashwin Ajay Debar Rasoul Alend Abdullah Benjamin Lee Wei En Knievel Mashida Marwan Al-Munaer Hanan Ajay Dileep Duvva Jean Mathew Adeoye Adenaya Gregory Y H Lip Rajiv Sankaranarayanan Source Type: research